【摘要】 目的 探讨辛伐他汀在治疗支气管哮喘（简称哮喘）合并高脂血症中的意义。方法 入选首都医科大学附属北京安贞医院72例哮喘患者,其中观察组（36例）为哮喘合并高脂血症患者,对照组（36例）为无高脂血症哮喘患者,治疗前评估肺功能[第1秒用力呼气容积（FEV₁）、呼气峰流速（PEF）]、静脉血免疫球蛋E（IgE）、酸性粒细胞（EOS）计数、哮喘控制测试（ACT）评分、哮喘控制问卷（ACQ-7）评分及每周使用急救药（万托林）的喷数。依据2009全球哮喘防治创议（GINA）进行规范化治疗,其中观察组同时服用辛伐他汀20 mg每晚1次,规范化治疗期为3个月。3个月后复查各项指标并收集数据。结果 2组间患者性别、年龄、病程、治疗前各指标差异无统计学意义（均P>0.05）。治疗后2组各指标与治疗前比较差异有统计学意义（均P<0.01）。治疗后,观察组的ACQ评分、EOS、IgE、FEV₁、PEF及每周急救药使用喷数与对照组比较,差异均有统计学意义[（1.35±0.14）分比（1.45±0.12）分,（129±50）×10⁹/L比（195±62）×10⁹/L,（77±32）kIU/L比（111±60）kIU/L,（80±9）%比（73±9）%,（353±68）L/min比（293±80）L/min,（2.1±1.1）喷/周比（3.5±1.9）喷/周,均P<0.01];ACT评分与对照组比较,差异无统计学意义[（21.6±2.0）分比（20.9±0.9）分,P>0.05]。结论 辛伐他汀治疗哮喘合并高脂血症效果较好。更多还原

【Abstract】 Objective To explore the effect of simvastatin in treatment of bronchial asthma complicated with hyperlipidemia.Methods All 72 cases of asthma were divided into observation group(complicated with hyperlipidemia) and control group(without hyperlipidemia).Lung function[forced expiratory volume in 1 second(FEV,),peak expiratory flow(PEF)],the amount of eosnophils(EOS) and immunoglobulin E(IgE) in the blood,the frequency of emergency medicine usage(ventolin) per week,and the results of both the asthma control test(ACT) and asthma control questionnaire(ACQ) were all recorded before the treatment.All cases were treated according to standards set by 2009 Global Initiative for Asthma(GINA).The observation group was also treated with 20 mg simvastatin Quaque Nocte for 3 months.After 3 months,the indicators were detected and data were collected.Results Gender,age,course of disease and the indicators before the treatment showed no statistical significance between the two groups(P >0.05).Compared with before treatment,the indicators showed statistical differences after treatment in two groups(P <0.01).After treatment,ACQ,EOS,IgE,FEV,,PEF and frequency of emergency medicine usage(ventolin) per week in die observation group had obvious statistical differences compared with the control group[(1.35 ±0.14) scores vs(1.45 ± 0.12) scores,(129 ± 50) × 10~9/L vs(195±62) ×l0~9/L,(77±32)kIU/ml vs(111 ±60)kIU/ml,(80 ±9)%vs(73 ±9)%,(353 ±68)L/min vs(293 ±80)L/min,(2.1 ±l.l)spray per week vs(3.5 ± 1.9) spray per week,allP<0.01].After treatment,ACT scores in the observation group had no statistical differences compared with die control group[(21.6 ±2.0)scores vs(20.9 ±0.9) scores,P > 0.05].Conclusion Simvastatin has a good effect in treatment of bronchial asthma complicated widi hyperlipidemia.更多还原